- Price
- $32.79
- Day
- -1.68%
- Mkt Cap
- $85.82M
- 52W Range
- $18.97 – $44.00
- Volume
- 27.9K
- Beta
- 0.28
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
HIGH POINT, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in September:
Read full article
HIGH POINT, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Read full article